Regeneron Pharmaceuticals, Inc. Common Stock REGN
i
Market dataready · fetched 2026-11-07T20:39:00.680Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-13
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-06T22:52:44.688359346Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-07T20:38:59.938852+00:00
Regeneron Pharmaceuticals, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 944.33 | 42.6% | 5.5% | 863.56 | 40.1% | 4.6% |
| 25Δ | 935.66 | 42.5% | 4.8% | 872.20 | 38.3% | 3.8% |
| 30Δ | 927.90 | 42.3% | 4.1% | 879.11 | 37.6% | 3.3% |
| 35Δ | 921.46 | 43.3% | 3.7% | 885.24 | 37.0% | 2.8% |
| 40Δ | 914.66 | 43.1% | 3.2% | 891.00 | 36.2% | 2.4% |
| 45Δ | 908.64 | 45.1% | 2.9% | 896.34 | 35.5% | 2.0% |
| 50Δ | 902.13 | 46.2% | 2.5% | 901.44 | 34.8% | 1.7% |
| 55Δ | 895.37 | 47.4% | 2.2% | 906.38 | 33.9% | 1.4% |
| 60Δ | 888.28 | 48.1% | 1.9% | 911.20 | 33.4% | 1.1% |
| 65Δ | 880.65 | 49.3% | 1.6% | 915.68 | 32.0% | 0.9% |
| 70Δ | 871.85 | 51.3% | 1.4% | 920.32 | 31.1% | 0.7% |
| 75Δ | 861.27 | 54.4% | 1.1% | 924.41 | 29.4% | 0.5% |
| 80Δ | 847.67 | 58.7% | 0.9% | 928.34 | 27.6% | 0.3% |
20Δ
- Pseudo strike
- 944.33
- IV
- 42.6%
- B/E move
- 5.5%
- Pseudo strike
- 863.56
- IV
- 40.1%
- B/E move
- 4.6%
25Δ
- Pseudo strike
- 935.66
- IV
- 42.5%
- B/E move
- 4.8%
- Pseudo strike
- 872.20
- IV
- 38.3%
- B/E move
- 3.8%
30Δ
- Pseudo strike
- 927.90
- IV
- 42.3%
- B/E move
- 4.1%
- Pseudo strike
- 879.11
- IV
- 37.6%
- B/E move
- 3.3%
35Δ
- Pseudo strike
- 921.46
- IV
- 43.3%
- B/E move
- 3.7%
- Pseudo strike
- 885.24
- IV
- 37.0%
- B/E move
- 2.8%
40Δ
- Pseudo strike
- 914.66
- IV
- 43.1%
- B/E move
- 3.2%
- Pseudo strike
- 891.00
- IV
- 36.2%
- B/E move
- 2.4%
45Δ
- Pseudo strike
- 908.64
- IV
- 45.1%
- B/E move
- 2.9%
- Pseudo strike
- 896.34
- IV
- 35.5%
- B/E move
- 2.0%
50Δ
- Pseudo strike
- 902.13
- IV
- 46.2%
- B/E move
- 2.5%
- Pseudo strike
- 901.44
- IV
- 34.8%
- B/E move
- 1.7%
55Δ
- Pseudo strike
- 895.37
- IV
- 47.4%
- B/E move
- 2.2%
- Pseudo strike
- 906.38
- IV
- 33.9%
- B/E move
- 1.4%
60Δ
- Pseudo strike
- 888.28
- IV
- 48.1%
- B/E move
- 1.9%
- Pseudo strike
- 911.20
- IV
- 33.4%
- B/E move
- 1.1%
65Δ
- Pseudo strike
- 880.65
- IV
- 49.3%
- B/E move
- 1.6%
- Pseudo strike
- 915.68
- IV
- 32.0%
- B/E move
- 0.9%
70Δ
- Pseudo strike
- 871.85
- IV
- 51.3%
- B/E move
- 1.4%
- Pseudo strike
- 920.32
- IV
- 31.1%
- B/E move
- 0.7%
75Δ
- Pseudo strike
- 861.27
- IV
- 54.4%
- B/E move
- 1.1%
- Pseudo strike
- 924.41
- IV
- 29.4%
- B/E move
- 0.5%
80Δ
- Pseudo strike
- 847.67
- IV
- 58.7%
- B/E move
- 0.9%
- Pseudo strike
- 928.34
- IV
- 27.6%
- B/E move
- 0.3%
Options history
Table
| Date | IV (%) |
|---|---|
| 28.93% | |
| 28.13% | |
| 26.55% | |
| 27.95% | |
| 25.90% | |
| 26.49% | |
| 26.77% | |
| 30.20% | |
| 29.93% | |
| 26.82% | |
| 27.53% | |
| 26.33% | |
| 27.68% | |
| 28.36% | |
| 24.20% | |
| 25.75% | |
| 25.54% | |
| 27.19% | |
| 27.82% | |
| 26.62% | |
| 30.00% | |
| 29.81% | |
| 29.72% | |
| 27.80% | |
| 29.73% | |
| 30.77% | |
| 29.99% | |
| 29.25% | |
| 26.83% | |
| 28.63% | |
| 27.98% | |
| 29.12% | |
| 30.84% | |
| 27.89% | |
| 30.22% | |
| 29.56% | |
| 30.33% | |
| 32.31% | |
| 29.06% | |
| 30.83% | |
| 30.63% | |
| 32.53% | |
| 33.65% | |
| 31.37% | |
| 34.12% | |
| 35.02% | |
| 36.73% | |
| 37.58% | |
| 38.23% | |
| 38.82% | |
| 38.26% | |
| 39.71% | |
| 43.52% | |
| 43.02% | |
| 46.80% | |
| 48.60% | |
| 52.35% | |
| 59.73% | |
| 34.78% |
Biotechnology
REPL
Replimune Group, Inc., a biotechnology company, develops oncolytic immunogenic therapies to treat cancer. The company is headquartered in Woburn, Massachusetts.
More →RGNX
REGENXBIO Inc., a clinical-stage biotechnology company, offers candidate gene therapy products to deliver genes to cells to address genetic defects or to enable cells in the body…
More →RIGL
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat blood disorders, cancer, and rare immune diseases. The company is…
More →RLAY
Relay Therapeutics, Inc. is a clinical-stage precision drug company. The company is headquartered in Cambridge, Massachusetts.
More →RLMD
Description unavailable
More →RNAC
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and…
More →